The ECDC says the region could still meet its testing targets for HIV, but that it will be harder to improve detection for ...

Enanta Pharmaceuticals recorded a narrower loss as sales rose in its fiscal fourth quarter driven by higher sales of a hepatitis C virus treatment.

Scientists have recently conducted a meta-analysis of over 150 research studies, and determined that infections with viruses ...

Patient Enrollment on Track in Global Phase 3 Program for Treatment of Hepatitis C Virus (HCV), Topline Results from North ...

Company Hosting Virtual KOL Panel Event Thursday, November 13th at 10:00 AM ETBOSTON, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Atea ...

A comprehensive guide to the most important health screenings men should begin after age 30, including checks for blood ...

Delayed administration of antibiotics was significantly linked to higher mortality among patients with acute-on-chronic liver ...

SHELTON, CONNECTICUT / ACCESS Newswire / November 10, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) today reported that it has received approval to Start Phase II Clinical Trial of ...

NanoViricides, Inc. (NYSE Amer.:NNVC) (the "Company"), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ending September 30, 2025 with the Securities and Exchange ...

VermontBiz A first-of-its-kind initiative, funded by a National Institute on Drug Abuse grant, will conduct an ambitious study to better understand trends in drug use and barriers to health care ...

WATERTOWN, Mass. - Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) reported a narrower-than-expected fourth-quarter loss on Monday, as the clinical-stage biotechnology company benefited from reduced ...

Secretary reviews Kashmir Province projects; PIs present research roadmaps spanning healthcare innovation, climate-resilient agriculture, food safety, infrastructure & digital governance SRINAGAR: Dr.